Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Vedanta Biosciences is raising $74,999,998.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Bernat Olle played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Vedanta Biosciences
Where Medicine Meets Ecology-The human body is an ecosystem. Trillions of microbes call us home. They form the human microbiome, which performs critical functions that preserve our health including modulating our immune system and providing colonization resistance against infectious pathogens. Alterations of the human microbiome are increasingly recognized as a key factor in development of immune and infectious diseases. We rationally design medicines based on consortia of human commensal bacteria to treat disease, using insights from microbial ecology, mucosal immunology, and human interventional studies.

To learn more about Vedanta Biosciences, visit http://www.vedantabio.com/

Contact:
Bernat Olle, Chief Executive Officer
857-706-1427
bolle@vedantabio.com
https://www.linkedin.com/in/bernat/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved